In a significant legal decision, a US appeals court has sided with Moderna on their COVID patent claims. Moderna, a prominent biotech company, has been at the forefront of developing mRNA-based vaccines for COVID-19. This ruling reinforces the company’s intellectual property rights and may have broader implications for the biotech industry’s approach to vaccine development. The decision could shape future licensing agreements and collaborations within the pharmaceutical sector, impacting the competitive landscape of the market.
Read more from reuters.com
